[
  {
    "ts": null,
    "headline": "Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet",
    "summary": "Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.",
    "url": "https://finnhub.io/api/news?id=d977b1b8dc36c11db8450529d4da450411bde98828725d0f2f74df3d0c05efc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771873050,
      "headline": "Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet",
      "id": 139187479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.",
      "url": "https://finnhub.io/api/news?id=d977b1b8dc36c11db8450529d4da450411bde98828725d0f2f74df3d0c05efc9"
    }
  },
  {
    "ts": null,
    "headline": "Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year",
    "summary": "Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.",
    "url": "https://finnhub.io/api/news?id=5ce23db19abddaf89179d5a3f4c8d0b735aa386faac3c169c42c1a7c0354c09c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771872541,
      "headline": "Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year",
      "id": 139187480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.",
      "url": "https://finnhub.io/api/news?id=5ce23db19abddaf89179d5a3f4c8d0b735aa386faac3c169c42c1a7c0354c09c"
    }
  },
  {
    "ts": null,
    "headline": "Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy",
    "summary": "Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions.",
    "url": "https://finnhub.io/api/news?id=26bef513e803cbb2663247227298bcb481af1230083b02a3259095146397203d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771872026,
      "headline": "Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy",
      "id": 139187481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions.",
      "url": "https://finnhub.io/api/news?id=26bef513e803cbb2663247227298bcb481af1230083b02a3259095146397203d"
    }
  },
  {
    "ts": null,
    "headline": "This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%",
    "summary": "GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.",
    "url": "https://finnhub.io/api/news?id=7a9398ff490ccdfddf654d132066beab40d756a196b13c9a0be03f62281406c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771871216,
      "headline": "This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%",
      "id": 139187482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.",
      "url": "https://finnhub.io/api/news?id=7a9398ff490ccdfddf654d132066beab40d756a196b13c9a0be03f62281406c3"
    }
  },
  {
    "ts": null,
    "headline": "Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY?",
    "summary": "Incyte Corporation recently reported past fourth-quarter 2025 results showing revenue of US$1,506.84 million and net income of US$299.28 million, alongside full-year 2025 revenue of US$5.14 billion and net income of US$1,286.65 million, and issued 2026 total net product revenue guidance of US$4.77 billion to US$4.94 billion. The sharp improvement in earnings and profitability, coupled with guidance that points to substantial product revenue, underscores how Incyte’s expanding oncology and...",
    "url": "https://finnhub.io/api/news?id=989aba699319070665e9b48863e39d1475869e21e3b14c4dd2cee3599108c048",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771866557,
      "headline": "Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY?",
      "id": 139186671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation recently reported past fourth-quarter 2025 results showing revenue of US$1,506.84 million and net income of US$299.28 million, alongside full-year 2025 revenue of US$5.14 billion and net income of US$1,286.65 million, and issued 2026 total net product revenue guidance of US$4.77 billion to US$4.94 billion. The sharp improvement in earnings and profitability, coupled with guidance that points to substantial product revenue, underscores how Incyte’s expanding oncology and...",
      "url": "https://finnhub.io/api/news?id=989aba699319070665e9b48863e39d1475869e21e3b14c4dd2cee3599108c048"
    }
  }
]